Obamacare Replacement May Improve Patient Access, Novartis Says
- Drugmakers want patients to have more access to new medicines
- Path ahead may not be as ‘draconian’ as feared, CEO says
Here's How Republicans Are Working to Repeal Obamacare
This article is for subscribers only.
Repealing and replacing Obamacare could benefit the pharmaceutical industry if it allows drugmakers to get cutting-edge new medicines to more U.S. patients, said Joe Jimenez, chief executive officer of Swiss health-care giant Novartis AG.
Parts of the Affordable Care Act, President Barack Obama’s signature health-care law, have made it hard for patients to get access to some new drugs because they have high co-pays or aren’t covered, Jimenez said in an interview on Thursday at the World Economic Forum in Davos, Switzerland.